- Home
- SUGP vs DWTX Comparison
SUGP vs DWTX Comparison
Compare SUGP & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- DWTX
- Stock Information
- Founded
- SUGP 1998
- DWTX 2012
- Country
- SUGP Hong Kong
- DWTX United States
- Employees
- SUGP N/A
- DWTX N/A
- Industry
- SUGP
- DWTX
- Sector
- SUGP
- DWTX
- Exchange
- SUGP NYSE
- DWTX NYSE
- Market Cap
- SUGP 9.6M
- DWTX 9.2M
- IPO Year
- SUGP 2024
- DWTX N/A
- Fundamental
- Price
- SUGP $0.50
- DWTX $4.82
- Analyst Decision
- SUGP
- DWTX Strong Buy
- Analyst Count
- SUGP 0
- DWTX 1
- Target Price
- SUGP N/A
- DWTX $10.00
- AVG Volume (30 Days)
- SUGP 146.6K
- DWTX 40.7K
- Earning Date
- SUGP 07-21-2025
- DWTX 08-14-2025
- Dividend Yield
- SUGP N/A
- DWTX N/A
- EPS Growth
- SUGP 1.19
- DWTX N/A
- EPS
- SUGP 0.11
- DWTX N/A
- Revenue
- SUGP $23,446,259.00
- DWTX N/A
- Revenue This Year
- SUGP N/A
- DWTX N/A
- Revenue Next Year
- SUGP N/A
- DWTX N/A
- P/E Ratio
- SUGP $4.70
- DWTX N/A
- Revenue Growth
- SUGP 11.29
- DWTX N/A
- 52 Week Low
- SUGP $0.35
- DWTX $1.62
- 52 Week High
- SUGP $3.25
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- SUGP 34.00
- DWTX N/A
- Support Level
- SUGP $0.47
- DWTX N/A
- Resistance Level
- SUGP $0.66
- DWTX N/A
- Average True Range (ATR)
- SUGP 0.08
- DWTX 0.00
- MACD
- SUGP -0.02
- DWTX 0.00
- Stochastic Oscillator
- SUGP 30.36
- DWTX 0.00
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.